Genomic Health, Inc. announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics’ IsoPSA™ reagents and technology. Initial efforts under this agreement will focus on Genomic Health’s development of a high-PSA (prostate-specific antigen) reflex test to accurately predict the presence of high-grade cancer (Gleason score >7) prior to prostate biopsy. The goal is …
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests

Recent Comments